Skip to the answer

Morphine

Morphine is a strong opioid pain medicine used to manage severe pain, in short-acting and long-acting oral forms, injections, and a rectal suppository form.

Brand names Arymo ERKadianMorphabondMS ContinAvinza +9 more
Drug class Opioid Agonist
Rx Schedule CII Forms 6
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 68 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

Other forms & routes:
Injection Rectal
Morphine at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Morphine is a strong opioid for severe pain that other treatments cannot control, acting on opioid receptors in the brain and spinal cord; it is the classic opioid others are measured against, on the market since about 1977 and available generically. Constipation hits nearly everyone and does not fade with time, while nausea and drowsiness usually ease within the first few days. Its boxed warning, the FDA’s strongest, covers addiction, overdose and life-threatening slowed breathing, so call 911 for shallow breathing or trouble waking, especially early on, after a dose increase, or if alcohol or sedatives are involved. Keep it locked away, because a child who swallows it can die.

Clinical pearls

  • Never crush, chew or dissolve extended-release forms; extended-release capsules can be sprinkled on applesauce and swallowed right away without chewing.
  • Measure the oral solution with a calibrated oral syringe and check milligrams versus milliliters, since strength mix-ups can cause overdose.
  • Ask for naloxone, the overdose-reversal medicine, to keep at home, and show family members where it is.
  • Tell prescribers you take it; benzodiazepines, gabapentin, pregabalin and sleep aids deepen sedation, while buprenorphine can weaken morphine or trigger withdrawal.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

The extended-release capsule label carries a boxed warning, the FDA's strongest warning. Morphine can cause addiction, life-threatening slowed breathing, and fatal overdose, especially if the capsules are crushed, chewed, or dissolved, or if you drink alcohol.

  • Swallow the capsules whole, or sprinkle the contents on applesauce and swallow without chewing.
  • Accidental ingestion, especially by children, can be fatal.
  • Do not drink alcohol or use products containing alcohol.
  • Combining with benzodiazepines or other sedating drugs can cause profound sleepiness, slowed breathing, coma, and death.
  • Using it for a long time during pregnancy can cause life-threatening withdrawal in the newborn.
  • Because of these risks, the FDA requires a safety program (REMS) for opioid pain medicines.
Read the full warning on DailyMed →
How you get itPrescription only
Comes asExtended-release tablet, Injection, Oral solution +3
Earliest FDA record1977
Companies listing it with the FDA28
FDA label last updatedMay 7, 2026
FDA’s strongest warning (boxed)Yes, read the warning

Patient information guide A plain-language walkthrough of Morphine, written from its FDA label.

What Morphine is used for

▾

Morphine is used for severe pain when other treatments are not enough.

  • Morphine Sulfate tablets: acute pain in adults and children weighing at least 50 kg, and chronic pain in adults.
  • Morphine Sulfate oral solution (2 mg/mL and 4 mg/mL): acute and chronic pain in adults, and acute pain in children 2 years and older.
  • Morphine Sulfate oral solution (20 mg/mL): acute and chronic pain in opioid-tolerant adults only.
  • Extended-release capsules and tablets, including MS Contin: severe, persistent pain needing daily long-term opioid treatment.
  • Morphine Sulfate injection: severe pain when other treatments are inadequate.
  • Duramorph and preservative-free morphine injection: pain managed by vein, or by epidural or intrathecal use.
  • Infumorph and Mitigo: continuous epidural or intrathecal infusion for intractable chronic pain.

How Morphine works

▾

Morphine attaches mainly to mu-opioid receptors in the brain and spinal cord. These receptors take part in how the body senses pain. By activating them, morphine relieves pain.

Unlike some pain relievers, it has no ceiling effect for pain relief. Doses are adjusted to relief and may be limited by side effects such as slowed breathing and sedation.

Morphine dosage

▾

Dosing is individualized, so follow your prescriber and label.

  • Oral forms are swallowed. Extended-release products must not be crushed, chewed, or dissolved.
  • Extended-release capsules can be taken with or without food, and are not for as-needed use.
  • Oral solution should be measured with a calibrated oral syringe.
  • Injections are given by healthcare professionals.

Dosing details from the FDA-approved label

From the Morphine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Adults (morphine sulfate tablets, first opioid analgesic; opioid-naïve or opioid-non-tolerant)
    • 15 mg to 30 mg every 4 hours as needed for pain, and at the lowest dose necessary to achieve adequate analgesia
    • Titrate the dose based upon the individual patient's response to their initial dose
  • Pediatric patients weighing at least 50 kg who are able to swallow oral tablets (morphine sulfate tablets)
    • 15 mg every 4 hours as needed for pain, and the lowest dose necessary to achieve adequate analgesia
    • Titrate the dose based upon the individual patient's response to their initial dose
    • Maximum: Do not exceed 30 mg as an initial dose
    • Not recommended for pediatric patients who weigh less than 50 kg
  • Conversion from parenteral morphine to morphine sulfate tablets
    • Anywhere from 3 to 6 mg of oral morphine sulfate may be required to provide pain relief equivalent to 1 mg of parenteral morphine
  • Conversion from other opioids to morphine sulfate tablets
    • Initiate dosing using morphine sulfate tablets 15 mg to 30 mg every 4 hours
    • Use a conservative approach; safer to underestimate the 24-hour dosage than to overestimate it
  • Opioid-naïve and opioid non-tolerant patients (morphine sulfate extended-release tablets)
    • Initiate with 15 mg tablets orally every 8 to 12 hours
  • Patients with established opioid tolerance (morphine sulfate extended-release 100 mg and 200 mg tablets)
    • Extended-release 100 mg and 200 mg tablets, a single dose greater than 60 mg, or a total daily dose greater than 120 mg, are only for use in patients in whom tolerance to an opioid of comparable potency has been established
    • Opioid-tolerant: taking for one week or longer at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Morphine Sulfate Oral Solution 20 mg/mL is only for opioid-tolerant adult patients . ( 2.1 ) Morphine Sulfate Oral Solution should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. ( 2.2 ) Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals. Reserve titration to higher doses of Morphine Sulfate Oral Solution for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. ( 2.2 , 5 ) Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic. Clinical guidelines on opioid prescribing for some acute pain conditions are available. ( 2.2 ) Initiate the dosing regimen for each patient individually, taking into account the patient’s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse. ( 2.2 , 5.2 ) Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with Morphine Sulfate Oral Solution. Consider this risk when selecting an initial dose and when making dose adjustments. ( 2.1 , 5.3 ) Discuss opioid overdose reversal agents and options for acquiring them with the patient and/or caregiver, both when initiating and renewing treatment with Morphine Sulfate Oral Solution, especially if the patient has additional risk factors for overdose, or close contacts at risk for exposure and overdose. ( 2.3 , 5.2 , 5.3 , 5.4 ). Adults: Initiate treatment with Morphine Sulfate Oral Solution 10 to 20 mg every 4 hours as needed for pain, and at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient’s response to their initial dose of Morphine Sulfate Oral Solution. ( 2.4 , 2.5 ) Pediatric Patients 2 Years of Age and Older: Initiate treatment with Morphine Oral Solution 2 mg/mL at a dose of 0.15 mg/kg to 0.3 mg/kg every 4 hours as needed for pain, and at the lowest dose necessary to achieve adequate analgesia. Do not exceed 20 mg as an initial dose in pediatrics.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Morphine side effects

▾

The most common side effects are:

Common side effects

  • Constipation
  • Nausea
  • Drowsiness or sleepiness
  • Dizziness
  • Anxiety
  • Vomiting
  • Itching
  • Dry mouth

When to get medical help

  • Slow or shallow breathing, extreme sleepiness, or trouble waking up. Call 911 right away.
  • Signs of overdose such as pinpoint pupils, cold clammy skin, or limp muscles. Get emergency help.
  • Signs of serotonin syndrome if you take other serotonin-affecting medicines.
  • Severe constipation or being unable to pass urine.
  • Lightheadedness or fainting from low blood pressure.
  • Signs of a serious allergic reaction (anaphylaxis).
  • Pain that gets worse as the dose goes up (opioid-induced hyperalgesia).
  • Thoughts of misuse, cravings, or signs of addiction. Tell your prescriber.

Morphine warnings and precautions

▾
  • Addiction, abuse, and misuse can occur even at recommended doses.
  • Life-threatening slowed breathing is most likely when starting or raising the dose.
  • Accidental ingestion, especially by children, can be fatal.
  • Alcohol and sedating drugs greatly raise the risk of death.
  • Prolonged use in pregnancy can cause newborn withdrawal.
  • Opioids can cause low blood pressure, adrenal insufficiency, and increased pain sensitivity.

Morphine interactions

▾

Several drugs and substances can make morphine riskier.

  • Alcohol: can cause a fatal overdose.
  • Benzodiazepines and other sedatives: profound sedation and slowed breathing.
  • MAO inhibitors: avoid within 14 days.
  • Serotonin-affecting drugs: risk of serotonin syndrome.
  • Buprenorphine, butorphanol, nalbuphine, pentazocine: may reduce effect or cause withdrawal.
  • Cimetidine and P-glycoprotein inhibitors: stronger morphine effects.
  • Diuretics and anticholinergics: reduced diuretic effect, or urinary retention and severe constipation.

Interactions listed in the FDA-approved label

From the Morphine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Alcohol: Concomitant use can result in an increase of morphine plasma levels and potentially fatal overdose of morphine. Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products containing alcohol during therapy.
  • Benzodiazepines and other CNS depressants: Due to additive pharmacologic effect, concomitant use can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers and educate them on signs and symptoms of respiratory depression. If concomitant use is warranted, consider recommending or prescribing an opioid overdose reversal agent.
  • Serotonergic drugs: Concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue morphine if serotonin syndrome is suspected.
  • Monoamine oxidase inhibitors (MAOIs): MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma). Do not use in patients taking MAOIs or within 14 days of stopping such treatment.
  • Mixed agonist/antagonist and partial agonist opioid analgesics: May reduce the analgesic effect of morphine and/or precipitate withdrawal symptoms. Avoid concomitant use.
  • Muscle relaxants: Morphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Decrease the dosage of morphine and/or the muscle relaxant as necessary. Consider recommending or prescribing an opioid overdose reversal agent.
  • Cimetidine: Concomitant use can potentiate morphine effects and increase risk of hypotension, respiratory depression, profound sedation, coma, and death. Evaluate patients for signs of respiratory depression that may be greater than expected and decrease the dosage of morphine and/or cimetidine as necessary.
  • Diuretics: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.
  • Anticholinergic drugs: Concomitant use may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Evaluate patients for signs of urinary retention or reduced gastric motility.
  • P-glycoprotein (PGP) inhibitors: Concomitant use can increase the exposure to morphine by about two-fold and can increase risk of hypotension, respiratory depression, profound sedation, coma, and death. Evaluate patients for signs of respiratory depression that may be greater than expected and decrease the dosage of morphine and/or the PGP-inhibitor as necessary.
Read the label’s full interactions text

7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with morphine sulfate extended-release capsules. Table 1: Clinically Significant Drug Interactions with Morphine Sulfate Extended-Release Capsules Alcohol Clinical Impact: Concomitant use of alcohol with morphine sulfate extended-release capsules can result in an increase of morphine plasma levels and potentially fatal overdose of morphine. Intervention: Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products containing alcohol while on morphine sulfate extended-release capsules therapy [see Warnings and Precautions (5.3) ]. Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. Intervention: Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of respiratory depression (including sedation) . If concomitant use is warranted, consider recommending or prescribing an opioid overdose reversal agent [see Dosage and Administration (2.1 , 2.2) , Warnings and Precautions (5.1 , 5.2 , 5.3) ] . Examples: Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol. Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿172 supplements and herbs with documented Morphine interactions, ranked by severity Check Morphine against a supplement or herb →

Before taking Morphine

▾
  • Do not use with significant breathing problems, severe asthma without monitoring, or a bowel blockage.
  • Do not use if allergic to morphine or on an MAO inhibitor.
  • Tell your doctor about substance misuse history or mental illness.
  • Use caution if elderly, frail, or with lung disease.
  • Tell your doctor about head injury, seizures, or low blood pressure.
  • Discuss pregnancy and breastfeeding, since morphine passes into breast milk.

Morphine overdose

▾

Overdose can cause slowed breathing, extreme sleepiness progressing to coma, limp muscles, cold clammy skin, and pinpoint pupils. Call 911 right away. Treatment focuses on supporting breathing and giving an overdose reversal agent such as naloxone or nalmefene, with prolonged monitoring for extended-release products.

What Morphine does in the body

▾

Morphine slows breathing by acting on the brainstem. It narrows the pupils and slows the gut, causing constipation. It can widen blood vessels, leading to low blood pressure, flushing, or itching. Long-term use can lower sex hormone levels.

How your body processes Morphine

▾

Only part of an oral morphine dose reaches the bloodstream because the liver breaks much of it down first. Extended-release capsules release morphine over about 24 hours. Morphine is processed mainly in the liver and cleared through the kidneys. Its half-life is about 2 hours after IV use and about 24 hours with extended-release capsules.

How to store Morphine

▾

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) . Protect from light and moisture. Dispense in a sealed, tamper-evident, child-resistant, light-resistant container.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

172

Supplements & herbs that interact with Morphine

172 supplements and herbal products have documented interactions with Morphine in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 8
  • Moderate · 138
  • Minor · 26
1,4-BUTANEDIOL Major ACTIVATED CHARCOAL Major BEER Major GAMMA-HYDROXYBUTYRATE (GHB) Major KAVA Major L-TRYPTOPHAN Major ST. JOHN'S WORT Major WINE Major +164 more
Every supplement checked against Morphine — ranked by severity The full interaction hub: 8 major · 138 moderate · 26 minor · every one linked to its full report. Check Morphine against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Morphine: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Morphine — the kind of thing our pharmacy team would talk through with you at the counter.

What is morphine used for?

▾
Morphine treats severe pain when other treatments haven't worked or aren't suitable. Some forms are short-acting, and others are long-acting for around-the-clock pain. Your prescriber chooses the form that fits your situation.

How should I take it?

▾
Follow your label exactly. Extended-release capsules and tablets must be swallowed whole, never crushed or chewed, because that can release a dangerous dose at once. For liquid, use a calibrated oral syringe, not a kitchen spoon.

Can I drink alcohol while taking it?

▾
No. Alcohol can raise morphine levels and cause a fatal overdose. Avoid products containing alcohol, and check with me before taking other sedating medicines like sleep aids or anxiety pills.

What side effects should I expect?

▾
Constipation, nausea, drowsiness, and dizziness are most common. Call for help right away if you have slow or shallow breathing, extreme sleepiness, fainting, or an allergic reaction.

How do I keep my family safe?

▾
Store it where children and others can't reach it, since even one dose can be fatal to a child. Ask about having naloxone at home, and dispose of unused medicine properly.

Is it safe in pregnancy?

▾
Using morphine for a long time during pregnancy can cause withdrawal in the newborn, which can be life-threatening if not treated. Tell your doctor if you are pregnant or planning to be so they can plan your care.

Is Morphine available over the counter?

▾
No. Morphine is a prescription medicine: every Morphine product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

Is Morphine a controlled substance?

▾
Yes — Morphine is a federally controlled substance (Schedule II) in the United States, so how it is prescribed, refilled and dispensed is regulated by the DEA.

When was Morphine first available?

▾
The earliest FDA record we hold for Morphine is from 1977: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Morphine was first used.

Who makes Morphine?

▾
28 companies currently list Morphine products in the FDA's NDC Directory, including Bryant Ranch Prepack, Hikma Pharmaceuticals USA Inc., Fresenius Kabi, USA LLC. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Morphine on HelloPharmacist

📊Morphine supplement interactions172 checked — ranked by severity 🌿Drug & Supplement CheckerMorphine vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Morphine NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Morphine Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Morphine forms and strengths (how it comes)

Morphine is available in 6 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Morphine inactive ingredients by manufacturer.

Extended-release tablet

By mouth
Brands MS Contin
How this form is used
What it may be used for
  • MS Contin is for severe, persistent pain that needs an opioid and cannot be treated well with other options, including immediate-release opioids.
  • Morphine Sulfate extended-release tablets are for severe pain needing daily, around-the-clock, long-term opioid treatment.
Important instructions
  • MS Contin is not for as-needed pain relief.
  • Morphine Sulfate extended-release tablets are not for as-needed use.
Available strengths 5 strengths
15 mg 30 mg 60 mg 100 mg 200 mg
124 FDA-listed product records ⓘ

Injection

Into a muscle · Into a vein · Into the epidural space · Into the fluid around the spinal cord
Brands Duramorph Infumorph 200 Infumorph 500 Mitigo
How this form is used
What it may be used for
  • Duramorph is for severe pain treated by vein, and for epidural or intrathecal pain management.
  • Infumorph and Mitigo are only for continuous epidural or intrathecal infusion for intractable chronic pain.
  • Morphine Sulfate injection is for severe pain when other treatments are inadequate.
Important instructions
  • Duramorph should be given by or under a physician experienced in epidural or intrathecal techniques.
  • Infumorph and Mitigo are not for single-dose intravenous, intramuscular, or subcutaneous use.
  • Mitigo and Infumorph require observation in a fully equipped setting for at least 24 hours after each test dose.
Available strengths 12 strengths
0.5 mg/mL 1 mg/0.5 mL 1 mg/mL 2 mg/mL 4 mg/mL 5 mg/mL
Show 6 more strengths Show fewer strengths
8 mg/mL 10 mg/mL 25 mg/mL 50 mg/mL 200 mg/20 mL 500 mg/20 mL
103 FDA-listed product records ⓘ

Oral solution

By mouth
Brands Opium Opium Tincture Deodorized
How this form is used
What it may be used for
  • Morphine Sulfate oral solution (2 mg/mL and 4 mg/mL) treats acute and chronic pain in adults and acute pain in children 2 years and older.
  • Morphine Sulfate oral solution (20 mg/mL) is only for opioid-tolerant adults.
Important instructions
  • Morphine Sulfate oral solution should be measured with a calibrated oral syringe, never a household spoon.
  • Morphine Sulfate oral solution comes in different strengths, so check mg versus mL carefully.
Available strengths 8 strengths
10 mg/0.5 mL 10 mg/5 mL 10 mg/mL 20 mg/5 mL 20 mg/mL 100 mg/5 mL
Show 2 more strengths Show fewer strengths
1 g/100 mL 10 g/1000 mL
69 FDA-listed product records ⓘ

Extended-release capsule

By mouth
Brands Kadian
How this form is used
What it may be used for
  • Morphine Sulfate extended-release capsules are for severe, persistent pain needing daily, long-term opioid treatment when other options are inadequate.
Important instructions
  • Morphine Sulfate extended-release capsules should be swallowed whole, or the contents sprinkled on applesauce and swallowed right away without chewing.
  • Morphine Sulfate extended-release capsules can be taken with or without food.
  • Morphine Sulfate extended-release capsules must not be crushed, chewed, or dissolved.
Available strengths 12 strengths
10 mg 20 mg 30 mg 40 mg 45 mg 50 mg
Show 6 more strengths Show fewer strengths
60 mg 75 mg 80 mg 90 mg 100 mg 120 mg
66 FDA-listed product records ⓘ

Tablet

By mouth
Brands MS Contin
How this form is used
What it may be used for
  • Morphine Sulfate tablets treat acute pain in adults and children weighing at least 50 kg, and chronic pain in adults.
Important instructions
  • Morphine Sulfate tablets should be used at the lowest effective dose for the shortest time needed.
Available strengths 3 strengths
15 mg 30 mg 60 mg
42 FDA-listed product records ⓘ

Rectal suppository

Rectal
Available strengths 4 strengths
5 mg 10 mg 20 mg 30 mg
16 FDA-listed product records ⓘ

Morphine on the U.S. market: products, makers and brands

How Morphine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

28 companies list 154 Morphine product records with the FDA, mostly as extended-release tablet, injection, oral solution; the earliest marketing or approval year on record is 1977. Brand names on the directory include Arymo ER, Kadian, Morphabond and 11 more; the rest are generics.

6
Dose forms ⓘ
28
Labelers (makers, repackagers, distributors)
10
Brand names
154
FDA-listed product records ⓘ
1977
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (11) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Bryant Ranch Prepack18%
Hikma Pharmaceuticals USA Inc.9%
Fresenius Kabi, USA LLC7%
American Health Packaging6%
Upsher-Smith Laboratories, LLC6%
Rhodes Pharmaceuticals LLC5%
Other makers49%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Morphine is used (Medicaid data)

A general measure of how commonly Morphine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Morphine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

562,550
Medicaid prescriptions filled (Q1–Q4 2025)
$18.4M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Morphine prescribed? Of the 1,601 medications we measure, Morphine ranks #252 by Medicaid prescriptions — more than 84% of them.

Where Morphine ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #252 of 1,601
#247 Benzoyl Peroxide 583,362 Rx #248 Iohexol 580,886 Rx #249 Estradiol Transdermal... 575,018 Rx #250 Olopatadine Ophthalmic 567,428 Rx #251 Isosorbide 563,613 Rx #252 Morphine 562,550 Rx #253 Chlorthalidone 561,590 Rx #254 Bisacodyl 542,387 Rx #255 Metronidazole Vaginal 541,965 Rx #256 Methotrexate 533,549 Rx #257 Labetalol 525,457 Rx

Utilization by Morphine product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 15 mg extended release oral tablet is the most-dispensed Morphine product — about 20% of these Medicaid prescriptions.

morphine sulfate 15 MG Extended Release Oral Tablet Most dispensed

114,853 Medicaid prescriptions (Q1–Q4 2025) 20% of Morphine prescriptions shown $2.3M gross reimbursement (before rebates) ≈ $20 per prescription (gross)

Summed across the 9 of 57 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 891881

morphine sulfate 30 MG Extended Release Oral Tablet

81,813 Medicaid prescriptions (Q1–Q4 2025) 15% of Morphine prescriptions shown $2.2M gross reimbursement (before rebates) ≈ $27 per prescription (gross)

Summed across the 8 of 51 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 891888

1 ML morphine sulfate 4 MG/ML Injection

78,802 Medicaid prescriptions (Q1–Q4 2025) 14% of Morphine prescriptions shown $2.1M gross reimbursement (before rebates) ≈ $27 per prescription (gross)

Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1732006

1 ML morphine sulfate 4 MG/ML Cartridge

73,039 Medicaid prescriptions (Q1–Q4 2025) 13% of Morphine prescriptions shown $2.1M gross reimbursement (before rebates) ≈ $29 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1732014

morphine sulfate 15 MG Oral Tablet

59,580 Medicaid prescriptions (Q1–Q4 2025) 11% of Morphine prescriptions shown $1.2M gross reimbursement (before rebates) ≈ $20 per prescription (gross)

Summed across the 5 of 27 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 892582

1 ML morphine sulfate 2 MG/ML Cartridge

39,916 Medicaid prescriptions (Q1–Q4 2025) 7% of Morphine prescriptions shown $2.1M gross reimbursement (before rebates) ≈ $53 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1729197

1 ML morphine sulfate 4 MG/ML Prefilled Syringe

29,939 Medicaid prescriptions (Q1–Q4 2025) 5% of Morphine prescriptions shown $2.4M gross reimbursement (before rebates) ≈ $82 per prescription (gross)

Summed across the 3 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 998213

1 ML morphine sulfate 2 MG/ML Prefilled Syringe

17,995 Medicaid prescriptions (Q1–Q4 2025) 3% of Morphine prescriptions shown $1M gross reimbursement (before rebates) ≈ $58 per prescription (gross)

Summed across the 3 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 998212

morphine sulfate 60 MG Extended Release Oral Tablet

16,971 Medicaid prescriptions (Q1–Q4 2025) 3% of Morphine prescriptions shown $704,072 gross reimbursement (before rebates) ≈ $41 per prescription (gross)

Summed across the 4 of 46 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 891893

morphine sulfate 30 MG Oral Tablet

16,478 Medicaid prescriptions (Q1–Q4 2025) 3% of Morphine prescriptions shown $582,351 gross reimbursement (before rebates) ≈ $35 per prescription (gross)

Summed across the 5 of 29 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 892672

1 ML morphine sulfate 10 MG/ML Injection

8,076 Medicaid prescriptions (Q1–Q4 2025) 1% of Morphine prescriptions shown $411,321 gross reimbursement (before rebates) ≈ $51 per prescription (gross)

Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1731993

morphine sulfate 20 MG/ML Oral Solution

7,657 Medicaid prescriptions (Q1–Q4 2025) 1% of Morphine prescriptions shown $153,811 gross reimbursement (before rebates) ≈ $20 per prescription (gross)

Summed across the 9 of 45 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 892625

1 ML morphine sulfate 2 MG/ML Injection

6,869 Medicaid prescriptions (Q1–Q4 2025) 1% of Morphine prescriptions shown $273,697 gross reimbursement (before rebates) ≈ $40 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2003714

morphine sulfate 2 MG/ML Oral Solution

3,282 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $52,793 gross reimbursement (before rebates) ≈ $16 per prescription (gross)

Summed across the 3 of 26 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 892589

morphine sulfate 100 MG Extended Release Oral Tablet

3,113 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $190,801 gross reimbursement (before rebates) ≈ $61 per prescription (gross)

Summed across the 3 of 32 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 891874

1 ML morphine sulfate 10 MG/ML Cartridge

1,283 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $85,953 gross reimbursement (before rebates) ≈ $67 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1731995

10 ML morphine sulfate 1 MG/ML Injection

825 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $86,769 gross reimbursement (before rebates) ≈ $105 per prescription (gross)

Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1728800

10 ML morphine sulfate 0.5 MG/ML Injection

447 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $19,313 gross reimbursement (before rebates) ≈ $43 per prescription (gross)

Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1728783

morphine sulfate 4 MG/ML Oral Solution

363 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $6,933 gross reimbursement (before rebates) ≈ $19 per prescription (gross)

Summed across the 2 of 13 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 894780

1 ML morphine sulfate 8 MG/ML Injection

272 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $1,877 gross reimbursement (before rebates) ≈ $6.90 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1732011

morphine sulfate 200 MG Extended Release Oral Tablet

214 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $30,358 gross reimbursement (before rebates) ≈ $142 per prescription (gross)

Summed across the 2 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 892646

20 ML morphine sulfate 25 MG/ML Injection

102 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $64,425 gross reimbursement (before rebates) ≈ $632 per prescription (gross)

Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1731522

1 ML morphine sulfate 10 MG/ML Prefilled Syringe

66 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $272 gross reimbursement (before rebates) ≈ $4.12 per prescription (gross)

Summed across the 1 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 894912

morphine sulfate 20 MG Extended Release Oral Capsule

50 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $6,686 gross reimbursement (before rebates) ≈ $134 per prescription (gross)

Summed across the 1 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 892596

20 ML morphine sulfate 10 MG/ML Injection

46 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $7,417 gross reimbursement (before rebates) ≈ $161 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1731998

morphine sulfate 10 MG Extended Release Oral Capsule

26 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $3,366 gross reimbursement (before rebates) ≈ $129 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 892494

24 HR morphine sulfate 30 MG Extended Release Oral Capsule

12 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $705 gross reimbursement (before rebates) ≈ $59 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 892342

Other Morphine products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)

461 Medicaid prescriptions (Q1–Q4 2025) <1% of Morphine prescriptions shown $200,388 gross reimbursement (before rebates) ≈ $435 per prescription (gross)

Summed across the 2 of 128 listed NDC products with Medicaid activity.

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Morphine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 79 of 535 listed Morphine NDCs with Medicaid activity.

Compare Morphine products

A representative set of FDA-listed product records for Morphine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 154 of 154 products — FDA National Drug Code Directory. See every product, package size and price: browse all 154 Morphine NDCs →

Morphine side effects reported to the FDA (FAERS)

After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Morphine — a signal of what to watch for, not proof the drug caused it.

The effects most often named in FDA reports that mention Morphine are drug dependence, pain, overdose; about 86% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.

191,646
Reports mentioning it
86%
Reported as serious
12
Distinct effects shown
Most reported effects
Drug Dependence
33,936
Pain
27,044
Overdose
25,456
Death
21,710
Emotional Distress
17,621
Toxicity To Various Agents
15,904
Drug Withdrawal Syndrome
14,603
Drug Hypersensitivity
12,512
Nausea
10,921
Vomiting
8,199
Age groups
Adult · 10,352Elderly · 5,117Neonate · 1,136Child · 397Infant · 328Adolescent · 296

Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Morphine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.

Morphine FDA approval history

How Morphine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.

Morphine was first approved by the FDA in 1977; the first generic version was approved in 1986. It remains available in U.S. pharmacies today.

1977
First FDA approval
1986
First generic approved
Lower-cost ANDA competition begins
2026
Available today
Active in U.S. pharmacies

Source: Drugs@FDA.

Morphine recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list 6 Morphine recalls since July 2021. Four of them are still ongoing or began in the last six months and are listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Ongoing Class I Aug 4, 2026 · Fresenius Kabi USA, LLC
Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.
  • Morphine Sulfate Injection, USP, 2 mg /mL, 1 mL single-dose Simplist prefilled syringes, For Intramuscular or Intravenous use, Rx only, Fresenius Kabi, Lake Zurich, IL. Unit of Use NDC Number 76045-0… Lots: Lot #: 6402820, Exp. Date 12/2028 FDA record D-0788-2026 →
Ongoing Class III Nov 26, 2025 · Winder Laboratories, LLC
Correct Labeled Product Mispack-Size stated on carton label did not match the size of the bottle in the carton.
  • Morphine Sulfate Oral Solution 100 mg / 5 mL (20 mg* / mL), 30 mL, Rx Only, For Oral Use Only, Manufactured By: /winder Laboratories, LLC, Winder, GA 30680. NDC: 75826-131-01 Lots: Lot 1312405; Exp 09/28/2027 FDA record D-0223-2026 →
Ongoing Class II Feb 6, 2025 · SUN PHARMACEUTICAL INDUSTRIES INC
Failed Dissolution Specifications
  • Morphine Sulfate Extended-Release Tablets, 100 mg, 100-count bottles, Rx Only, Manufactured by: Ohm Laboratories Inc., New Brunswick, NJ 08901. Distributed by: Sun Pharmaceutical Industries, Inc., Cr… Lots: Lot #: AD16615, Exp. Date 07/2025 FDA record D-0249-2025 →
Ongoing Class II Mar 12, 2024 · Hikma Pharmaceuticals USA Inc.
The filter included in the carton has an expiration date that has expired prior to the expiration date of the actual product lot.
  • Infumorph (Preservative-free Morphine Sulfate Sterile Solution), 20 mL ampul, Rx only, Manufactured by Hikma Berkeley Heights, NJ 07922, NDC 0641-6039-01 Lots: Lot #: 052001, 052003, Exp. Date 11/2024; 023012, 023014, Exp. Date 08/2024 FDA record D-0392-2024 →
Class III Oct 20, 2023 · Terminated · Edenbridge Pharmaceuticals, LLC
Subpotent Drug
  • Opium Tincture, USP (Deodorized), 10 mg/mL of anhydrous morphine, packaged in 118 mL (4 Fl oz) bottles, Rx only, Manufactured for: Edenbridge Pharmaceuticals, LLC Parsippany, NJ 07054, NDC 42799-217-… Lots: Lot#: 23ZCP1, Exp. Date 02/22/2026;Lot #:23ZDR1, Exp. Date 03/09/2026 FDA record D-0080-2024 →
Class II Sep 17, 2021 · Terminated · Fresenius Kabi USA LLC
Defective container: Cracked vials leading to lack of sterility assurance
  • Morphine Sulfate Injection, USP, 2 mg per mL, 1 mL single dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-452-01. 25 vials per tray packaged 18 trays per shipper Lots: Lot # 6023731, 6023732, Exp 03/2023; 6024172, 6024260, Exp 06/2023 FDA record D-0856-2021 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Morphine RxCUI 7052 12 dose forms · 79 strengths
  1. Dose form (SCDF) Auto-Injector RxCUI 1731577 In current FDA listings
    Clinical drug / strength (SCD) 0.7 ML morphine sulfate 14.3 MG/ML RxCUI 894911
  3. Dose form (SCDF) Extended Release Oral Capsule RxCUI 374654 In current FDA listings
    Clinical drug / strength (SCD) sulfate 10 MG RxCUI 892494 sulfate 100 MG RxCUI 892554 sulfate 20 MG RxCUI 892596 sulfate 30 MG RxCUI 892345 sulfate 40 MG RxCUI 1303736 sulfate 50 MG RxCUI 894801 sulfate 60 MG RxCUI 892352 sulfate 80 MG RxCUI 894814 24 HR morphine sulfate 120 MG RxCUI 892297 24 HR morphine sulfate 30 MG RxCUI 892342 24 HR morphine sulfate 45 MG RxCUI 894942 24 HR morphine sulfate 60 MG RxCUI 892349 24 HR morphine sulfate 75 MG RxCUI 894970 24 HR morphine sulfate 90 MG RxCUI 892355
  5. Dose form (SCDF) Injectable Solution RxCUI 372956 In current FDA listings
    Clinical drug / strength (SCD) sulfate 10 MG/ML RxCUI 892531 sulfate 15 MG/ML RxCUI 895194 sulfate 20 MG/ML RxCUI 895202 sulfate 30 MG/ML RxCUI 895213 sulfate liposomal 10 MG/ML RxCUI 895975
  6. Dose form (SCDF) Injection RxCUI 1728776 In current FDA listings
    Clinical drug / strength (SCD) 1 ML morphine sulfate 10 MG/ML RxCUI 1731993 1 ML morphine sulfate 2 MG/ML RxCUI 2003714 1 ML morphine sulfate 4 MG/ML RxCUI 1732006 1 ML morphine sulfate 5 MG/ML RxCUI 1732136 1 ML morphine sulfate 8 MG/ML RxCUI 1732011 1.5 ML morphine sulfate liposomal 10 MG/ML RxCUI 1731990 2 ML morphine sulfate 0.5 MG/ML RxCUI 1728791 2 ML morphine sulfate 1 MG/ML RxCUI 1728805 4 ML morphine sulfate 25 MG/ML RxCUI 1731520 10 ML morphine sulfate 0.5 MG/ML RxCUI 1728783 10 ML morphine sulfate 1 MG/ML RxCUI 1728800 20 ML morphine sulfate 10 MG/ML RxCUI 1731998 20 ML morphine sulfate 25 MG/ML RxCUI 1731522 20 ML morphine sulfate 50 MG/ML RxCUI 1731537 30 ML morphine sulfate 1 MG/ML RxCUI 1728999 30 ML morphine sulfate 5 MG/ML RxCUI 1732138 50 ML morphine sulfate 50 MG/ML RxCUI 1731545
  7. Dose form (SCDF) Oral Capsule RxCUI 372961 No current FDA listing
    Clinical drug / strength (SCD) sulfate 15 MG RxCUI 892579 sulfate 30 MG RxCUI 892669
  8. Dose form (SCDF) Oral Solution RxCUI 106841 In current FDA listings
    Clinical drug / strength (SCD) sulfate 10 MG/ML RxCUI 895016 sulfate 2 MG/ML RxCUI 892589 sulfate 20 MG/ML RxCUI 892625 sulfate 4 MG/ML RxCUI 894780 sulfate 6 MG/ML RxCUI 895238
  9. Dose form (SCDF) Oral Suspension RxCUI 895012 No current FDA listing
    Clinical drug / strength (SCD) sulfate 2 MG/ML RxCUI 895199 sulfate 3 MG/ML RxCUI 895208 sulfate 5 MG/ML RxCUI 895219 sulfate 6.67 MG/ML RxCUI 895240
  10. Dose form (SCDF) Oral Tablet RxCUI 372959 In current FDA listings
    Clinical drug / strength (SCD) sulfate 10 MG RxCUI 895014 sulfate 15 MG RxCUI 892582 sulfate 20 MG RxCUI 895201 sulfate 200 MG RxCUI 895206 sulfate 30 MG RxCUI 892672 sulfate 50 MG RxCUI 895221 sulfate 60 MG RxCUI 895247
  12. Dose form (SCDF) Rectal Suppository RxCUI 372957 In current FDA listings
    Clinical drug / strength (SCD) sulfate 10 MG RxCUI 892516 sulfate 100 MG RxCUI 895022 sulfate 15 MG RxCUI 895185 sulfate 20 MG RxCUI 892603 sulfate 30 MG RxCUI 892678 sulfate 35 MG RxCUI 895215 sulfate 5 MG RxCUI 894807 sulfate 50 MG RxCUI 895227 sulfate 75 MG RxCUI 895248

Look up RxCUI 7052 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Morphine supply and shortage status

Whether Morphine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.

Morphine is currently listed in shortage by the FDA (10 presentations on record).

⚠️Currently in shortage (FDA) — Morphine

See the Morphine shortage pages — affected NDCs, other makers, and what to do →

Current Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)
Hospira, Inc., a Pfizer Company · Since 10/31/2017 · Updated 09/22/2026
Current Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)
Hospira, Inc., a Pfizer Company · Since 10/31/2017 · Updated 09/22/2026
Current Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)
Hospira, Inc., a Pfizer Company · Since 10/31/2017 · Updated 09/22/2026
Reason: Other
Current Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)
Hospira, Inc., a Pfizer Company · Since 10/31/2017 · Updated 09/22/2026
Current Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)
Hospira, Inc., a Pfizer Company · Since 10/31/2017 · Updated 09/22/2026
Reason: Other
Current Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)
Hospira, Inc., a Pfizer Company · Since 10/31/2017 · Updated 09/22/2026
Current Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)
Hospira, Inc., a Pfizer Company · Since 10/31/2017 · Updated 09/22/2026
Reason: Discontinuation of the manufacture of the drug
Current Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)
Hospira, Inc., a Pfizer Company · Since 10/31/2017 · Updated 09/22/2026
Reason: Other
Current Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)
Hikma Pharmaceuticals USA, Inc. · Since 11/03/2017 · Updated 09/18/2026
Reason: Demand increase for the drug
Current Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)
Hikma Pharmaceuticals USA, Inc. · Since 11/03/2017 · Updated 09/18/2026

Source: openFDA, from the FDA Drug Shortages database.

💵 What Morphine costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Tablet, Film Coated, Extended Release · Oral 15 mg $0.310 per tablet NDC details & price history
Tablet, Film Coated, Extended Release · Oral 30 mg $0.441 per tablet NDC details & price history
Tablet, Film Coated, Extended Release · Oral 60 mg $0.657 per tablet NDC details & price history
Tablet, Film Coated, Extended Release · Oral 200 mg $2.13 per tablet NDC details & price history
Tablet, Film Coated, Extended Release · Oral 100 mg $0.854 per tablet NDC details & price history
Solution · Oral 100 mg/5 mL $0.302–$0.460 per mL NDC details & price history
Solution · Oral 20 mg/mL $0.302–$0.460 per mL NDC details & price history
Solution · Oral 10 mg/5 mL $0.043–$0.092 per mL NDC details & price history
Solution · Oral 20 mg/5 mL $0.068–$0.120 per mL NDC details & price history
Solution · Oral 1 g/100 mL $2.86 per mL NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Morphine brand names

Morphine is sold under 14 brand names in the FDA directory — Arymo ER, Kadian, Morphabond, MS Contin and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Arymo ER Kadian Morphabond MS Contin Avinza Oramorph SR Roxanol-T Infumorph Mitigo Duramorph Opium Tincture Deodorized Infumorph 200 Infumorph 500 Opium

Who makes Morphine: manufacturers and labelers

28 companies list Morphine products with the FDA. By number of product records, the largest are Bryant Ranch Prepack, Hikma Pharmaceuticals USA Inc., Fresenius Kabi, USA LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Bryant Ranch Prepack 27 Hikma Pharmaceuticals USA Inc. 14 Fresenius Kabi, USA LLC 11 American Health Packaging 10 Upsher-Smith Laboratories, LLC 9 Rhodes Pharmaceuticals LLC 8 SpecGx LLC 8 Amneal Pharmaceuticals of New York LLC 7 Hospira, Inc. 7 Actavis Pharma, Inc. 6 Nortec Development Associates, Inc. 6 Precision Dose, Inc. 6 Lupin Pharmaceuticals,Inc. 5 Sun Pharmaceutical Industries, Inc. 5 Major Pharmaceuticals 4 Padagis US LLC 4 Winder Laboratories LLC 3 Ascend Laboratories, LLC 2 PAI Holdings, LLC dba PAI Pharma 2 Piramal Critical Care, Inc. 2 ANI Pharmaceuticals, Inc. 1 Civica, Inc. 1 Cranbury Pharmaceuticals, LLC 1 Edenbridge Pharmaceuticals, LLC 1

…and 4 more on the FDA NDC directory.

Morphine drug class (RxNorm)

Morphine belongs to the Opioid Agonist class.

Pharmacologic class Opioid Agonist
Drug family (ATC) Natural opium alkaloids
How it works Full Opioid Agonists

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Morphine page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective May 7, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Morphine.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Morphine after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
68
Finished products in the current FDA directory
154
Companies listing them (makers, repackagers, distributors)
28
FDA labeler codes behind them ⓘ
34
Linked representative label ⓘ
Genus Lifesciences Inc.
Linked label effective
May 7, 2026
Composite sections available
27
Linked SPL Set ID
8a77894b-2137-4f46-8dff-5c7b773d4d16
Linked SPL Document ID
b937d1d0-9ed8-4aa3-9e4a-cce02870e7e9
Open the linked representative label on DailyMed ↗
NDC package records associated with this linked SPL 1

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Genus Lifesciences Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →